TENANTS

Archive | Resident Company News

Instgram-1080x1080

Emerging firms will pitch over two days at 2018 Wisconsin Early Stage Symposium

Forty young companies will pitch to potential investors and others throughout the course of the Nov. 7-8 Wisconsin Early Stage Symposium at Madison’s Monona Terrace Convention Center. That includes 24 companies selected by conference organizers to present Nov. 7 during the Tech Council Investor Networks tracks and 16 more picked for the fast-moving Elevator Pitch […]

Continue Reading
Cologuard®

Cologuard® Revenue Increased 63 Percent To $118 Million, And Cologuard Test Volume Grew 49 Percent To 241,000 During Third Quarter

– Demand accelerated from healthcare providers as more than 11,000 ordered their initial Cologuard test during the third quarter, and nearly 132,000 have ordered since the test was launched – Gross margin increased 320 basis points to 75 percent – Exact Sciences now has in-network contracts with all five top commercial health plans, increasing patient […]

Continue Reading
iStock_3186804XSmall-antibodies-cancer

Invenra, Madison Firm Developing Therapeutic Antibodies, Adds $7.1M

Xconomy Wisconsin — Invenra, a Madison, WI-based startup that develops therapeutic antibodies for pharmaceutical companies and other clients, has raised more than $7.1 million from investors, according to a regulatory filing. Twenty-three investors participated in the equity funding round, according to the filing, which was made public earlier this week. Founded in 2011, Invenra has […]

Continue Reading
Forward BIO Institute

Forward BIO Institute awarded $5 million NIH grant

UW-Madison’s Forward BIO Institute has been awarded $5 million from the National Institutes of Health for tissue manufacturing. The grant was announced yesterday at the Biohealth Summit by Professor Bill Murphy, the institute’s director. “This is a unique public-private collaboration that’s committed to advancing the global biomanufacturing industry,” he said. “We want to train the […]

Continue Reading
Forward+BIOLABS

Forward BIOLABS to host early stage life sciences startups

The recently announced Forward BIOLABS will serve as a landing place for startups, many of which will come out of UW-Madison research. That’s according to co-founder Jessica Martin Eckerly. She says the nonprofit’s goal is to establish a fully equipped life sciences laboratory for early-stage companies, making it easier for them to bring their ideas […]

Continue Reading
ARROWHEAD-BUILDING

Arrowhead Pharmaceuticals inks $250M deal with Janssen Pharmaceuticals that could grow to $3.7B

Arrowhead Pharmaceuticals says it has reached a licensing and collaboration agreement with Janssen Pharmaceuticals that will bring the company $250 million to start and ultimately could be worth as much as $3.7 billion. Janssen will get the worldwide exclusive license for ARO-HBV, a drug that treats chronic hepatitis B, and an option to collaborate with […]

Continue Reading
FluGen_weblogo

Children are the latest test subjects of FluGen’s universal flu vaccine

An influenza vaccine developed by FluGen, of Madison, is being tested on children and teenagers in a clinical trial that’s being subsidized by a division of the National Institutes of Health. The test began in August, according to a statement last week by the National Institute of Allergy and Infectious Diseases. Fifty healthy children between […]

Continue Reading
D2P Innovation to Market

Discovery to Product creates new program to grow entrepreneurship at UW–Madison

Discovery to Product, which supports and mentors faculty, staff and student innovators and entrepreneurs on campus, is offering a new program called Innovation to Market. The fall I2M program builds on the success of D2P’s Igniter program cohorts that helped start 19 companies over the past three years. “The goals of D2P, located within the […]

Continue Reading
NeuroPoint

NeuroPointDX Biological test for autism could lead to earlier identification

A new study from NeuroPointDX of Madison and University of California researchers shows biochemical markers could allow for earlier identification of autism spectrum disorder. Lead author David Amaral says this discovery could also lead to avenues for therapeutic intervention. NeuroPointDX is a division of Stemina Biomarker Discovery, also based in Madison, and Amaral is from […]

Continue Reading